本帖最后由 老马 于 2012-1-13 21:20 编辑
, j1 Q) ?# F2 w
w N0 X2 R+ s, ^爱必妥和阿瓦斯丁的比较: _, L6 I6 {) K& ~, G; w( ^- {3 B
" K: s" {0 ~6 t
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/4 X: P; y }- r
5 Z7 p, I4 `9 ^& K$ v
/ K/ r# `, f. j: L5 e1 U n* Shttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 D/ E' c* T' A+ Y" l
==================================================
; _, [- A8 o* x0 _7 gOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 s( \" x6 _; h2 b7 zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" ?5 B6 u7 A2 h' Y7 F/ x2 t( sResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 F# t4 d! U# @2 }
|
显身卡
